🟢 Moleculin Biotech is trading 2.6% up in pre-market after announcing new September Annamycin data presentations

Moleculin Biotech is trading at $0.80, up 2.6% in pre-market after announcing new Annamycin data presentations.

• On September 14, Moleculin Biotech announced new Annamycin data will be presented at three September scientific meetings, including an AACR pancreatic-cancer conference.
• Topics include pancreatic-cancer antitumor activity, tissue concentration, topoisomerase II targeting, and possible CD8+ T-cell involvement.
• The company-specific announcement is the clearest catalyst; broader markets are modestly weaker. September 14 close: $0.78, up 8.42%.